Mirati - oncology?

























Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago


Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago

If you love investing in stocks you're bound to buy some losers. Long term Mirati Therapeutics, Inc.(NASDAQ:MRTX) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 57% drop in the share price over that period. The more recent news is of little comfort, with the share price down 52% in a year. Unfortunately the share price momentum is still quite negative, with prices down 9.1% in thirty days.
 






Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago


Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago

If you love investing in stocks you're bound to buy some losers. Long term Mirati Therapeutics, Inc.(NASDAQ:MRTX) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 57% drop in the share price over that period. The more recent news is of little comfort, with the share price down 52% in a year. Unfortunately the share price momentum is still quite negative, with prices down 9.1% in thirty days.

Meek and his bad toupee must go.